Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Axsome Therapeutics (AXSM) Other Operating Expenses (2022 - 2025)

Axsome Therapeutics (AXSM) has disclosed Other Operating Expenses for 4 consecutive years, with $51.1 million as the latest value for Q4 2025.

  • Quarterly Other Operating Expenses rose 120.98% to $51.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $97.6 million through Dec 2025, up 43.87% year-over-year, with the annual reading at $51.4 million for FY2025, 24.24% down from the prior year.
  • Other Operating Expenses hit $51.1 million in Q4 2025 for Axsome Therapeutics, up from $26.7 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $52.2 million in Q4 2023 to a low of -$45.3 million in Q3 2022.
  • Historically, Other Operating Expenses has averaged $12.9 million across 4 years, with a median of $11.8 million in 2024.
  • Biggest five-year swings in Other Operating Expenses: skyrocketed 90170.07% in 2023 and later crashed 55.73% in 2024.
  • Year by year, Other Operating Expenses stood at -$57946.0 in 2022, then surged by 90170.07% to $52.2 million in 2023, then tumbled by 55.73% to $23.1 million in 2024, then skyrocketed by 120.98% to $51.1 million in 2025.
  • Business Quant data shows Other Operating Expenses for AXSM at $51.1 million in Q4 2025, $26.7 million in Q3 2025, and $6.9 million in Q2 2025.